AC Immune SA

NASDAQ
ACIU
paper.types.company
Rentabilité sur six mois: -49.7%
Rendement en dividendes: 0%
Secteur: Healthcare

1.69 $

0 $ 0%
1.48 $
4.73 $

paper.min_max_per_year

Calendrier des promotions AC Immune SA

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise AC Immune SA

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

plus de détails
The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Paramètres de base

IPO date
2016-09-23
ISIN
CH0329023102
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
chf
Сайт
lien
Tous les paramètres

Grade

Sous-estimation
Nom Signification Grade
P/S 8.94 1
P/BV 2.18 7
P/E 0 0
Efficacité
Nom Signification Grade
ROA -24.61 0
ROE -37.31 0
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA -0.1116 10
Debt/Ratio 0.0235 10
Debt/Equity 1.06 8
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % 76.97 8
Rentabilité Ebitda, % -17.9 0
Rentabilité EPS, % -39.2 0
Plus de détails

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 1.69 $ 0 $ 0 $ 0 % 0 % 0 %
common.calendar.number_days.7d 1.65 $ 0 $ 0 $ 2.42 % 0 % 0 %
common.calendar.number_days.30d 1.7 $ 1.53 $ 1.75 $ -0.59 % 0 % 0 %
common.calendar.number_days.90d 2.52 $ 1.48 $ 2.32 $ -32.94 % 0 % 0 %
common.calendar.number_days.180d 3.36 $ 1.48 $ 2.99 $ -49.7 % 0 % 0 %
common.calendar.number_days.1y 3.97 $ 1.48 $ 4.73 $ -57.43 % 0 % 0 %
common.calendar.number_days.3y 3.26 $ 1.48 $ 5 $ -48.16 % 0 % 0 %
common.calendar.number_days.5y 7.48 $ 1.48 $ 9.06 $ -77.41 % 0 % 0 %
common.calendar.number_days.10y 0 $ 1.48 $ 19.3 $ 0 % 0 % 0 %
common.calendar.number_days.ytd 2.7 $ 1.48 $ 2.98 $ -37.41 % 0 % 0 %

Principaux propriétaires

Contenu dans l'ETF

ETFPartager, %Rentabilité pour l'année, %Commission, %
Principal Healthcare Innovators ETF 0.03418 -3.92 0.35
Future Tech ETF 0.03418 -18.13 0.35
0,03-11,030,35

Entreprises similaires

P/E & P/BVEV/Ebitda & Debt/Ebitda


Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Dr. Andrea Pfeifer Ph.D. Co-Founder, CEO & Director 1.1M 1957 (68 années)
Mr. Christopher Roberts CFO & VP of Finance N/A 1990 (35 années)
Mr. Piergiorgio Donati Chief Technical Operations Officer N/A 1971 (54 année)
Mr. Jean-Fabien Monin Chief Administrative Officer N/A 1971 (54 année)
Mr. Howard Donovan Chief HR Officer N/A 1976 (49 années)
Mr. Alexandre Caratsch General Counsel N/A 1966 (59 années)
Mr. Julian Snow VP of U.S. Finance & Corporate Development N/A
Ms. Madiha Derouazi Chief Scientific Officer N/A 1973 (52 année)
Dr. Gary Anthony Waanders Ph.D. Senior VP of Investor Relations & Corporate Communications N/A 1964 (61 année)
Dr. David T. Hickman Head of AD - SME

Informations sur l'entreprise

Adresse: Switzerland, Lausanne, Building B - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://www.acimmune.com